Can bimekizumab delay early plaque psoriasis?
Treatments studied
Part of Skin clinical trials.
This trial tests if the drug bimekizumab can slow down chronic inflammation in people with early plaque psoriasis. It's for adults 18-44 with mild psoriasis who haven't used topical treatments recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 44 years old.
- You have plaque psoriasis (red, scaly patches) without psoriatic arthritis.
- You have mild psoriasis, affecting a small area of your body.
- You have at least one spot on your elbows, knees, or lower back.
- You haven't used any psoriasis creams or ointments in the last 2 weeks.
- Women: You agree to use effective birth control or are not able to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This study tests whether a higher dose of guselkumab (a biologic medicine) given less frequently works as well as the standard dose for treating moderate-to-severe plaque psoriasis. The goal is to find a dosing schedule that is both effective and convenient for patients.
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study looks at whether giving bimekizumab in different ways is safe and how it moves through the body over time. It is for adults with active psoriatic arthritis or axial spondyloarthritis who may benefit from bimekizumab treatment.
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.